IL186131A0 - Injectable depot formulations and methods for providing sustained release of nanoparticle compositions - Google Patents
Injectable depot formulations and methods for providing sustained release of nanoparticle compositionsInfo
- Publication number
- IL186131A0 IL186131A0 IL186131A IL18613107A IL186131A0 IL 186131 A0 IL186131 A0 IL 186131A0 IL 186131 A IL186131 A IL 186131A IL 18613107 A IL18613107 A IL 18613107A IL 186131 A0 IL186131 A0 IL 186131A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- sustained release
- nanoparticle compositions
- injectable depot
- depot formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67112405P | 2005-04-13 | 2005-04-13 | |
| PCT/IB2006/001094 WO2006109183A1 (en) | 2005-04-13 | 2006-04-10 | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL186131A0 true IL186131A0 (en) | 2008-01-20 |
Family
ID=36602931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL186131A IL186131A0 (en) | 2005-04-13 | 2007-09-20 | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080193542A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1874268A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008538751A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070119678A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101166514A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2006233345A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0609299A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2605153A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL186131A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007012103A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ561950A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2407529C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006109183A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200708188B (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1623703B1 (en) | 1999-10-29 | 2011-10-05 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| HU230875B1 (hu) | 2000-10-30 | 2018-11-29 | Euro-Celtique S.A. | Szabályozott hatóanyag-leadású hidrokodon készítmények |
| TW200526221A (en) * | 2003-09-02 | 2005-08-16 | Imran Ahmed | Sustained release dosage forms of ziprasidone |
| US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| JP2008546781A (ja) * | 2005-06-20 | 2008-12-25 | エラン・ファルマ・インターナショナル・リミテッド | アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物 |
| HK1117060A1 (en) * | 2005-06-20 | 2009-01-09 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds |
| EP2175857B1 (en) * | 2007-07-12 | 2013-09-11 | Janssen R&D Ireland | Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| JP5893616B2 (ja) | 2010-10-18 | 2016-03-23 | 大日本住友製薬株式会社 | 注射用徐放性製剤 |
| RS60651B1 (sr) | 2011-04-15 | 2020-09-30 | Janssen Pharmaceutica Nv | Nanosuspenzije leka osušene zamrzavanjem |
| CN104814926A (zh) * | 2015-04-08 | 2015-08-05 | 中国药科大学 | 一种鲁拉西酮纳米混悬剂及其制备方法 |
| MX2018003380A (es) * | 2015-09-21 | 2018-08-16 | Teva Pharmaceuticals Int Gmbh | Formulaciones de olanzapina de liberacion sostenida. |
| CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| CN109998991A (zh) * | 2019-04-28 | 2019-07-12 | 中国药科大学 | 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法 |
| KR102847306B1 (ko) * | 2021-08-13 | 2025-08-18 | 단국대학교 천안캠퍼스 산학협력단 | 결정형 몬테루카스트를 포함하는 지속성 현탁 주사제 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| EP1575616A2 (en) * | 2002-10-25 | 2005-09-21 | Pfizer Products Inc. | Novel injectable depot formulations |
| US7488729B2 (en) * | 2002-12-04 | 2009-02-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| TW200526221A (en) * | 2003-09-02 | 2005-08-16 | Imran Ahmed | Sustained release dosage forms of ziprasidone |
-
2006
- 2006-04-10 WO PCT/IB2006/001094 patent/WO2006109183A1/en not_active Ceased
- 2006-04-10 BR BRPI0609299-3A patent/BRPI0609299A2/pt not_active IP Right Cessation
- 2006-04-10 KR KR1020077023308A patent/KR20070119678A/ko not_active Abandoned
- 2006-04-10 US US11/911,457 patent/US20080193542A1/en not_active Abandoned
- 2006-04-10 CA CA002605153A patent/CA2605153A1/en not_active Abandoned
- 2006-04-10 NZ NZ561950A patent/NZ561950A/en not_active IP Right Cessation
- 2006-04-10 CN CNA2006800144209A patent/CN101166514A/zh active Pending
- 2006-04-10 MX MX2007012103A patent/MX2007012103A/es not_active Application Discontinuation
- 2006-04-10 RU RU2007137846/15A patent/RU2407529C2/ru not_active IP Right Cessation
- 2006-04-10 EP EP06744618A patent/EP1874268A1/en not_active Withdrawn
- 2006-04-10 AU AU2006233345A patent/AU2006233345A1/en not_active Abandoned
- 2006-04-10 JP JP2008505990A patent/JP2008538751A/ja not_active Withdrawn
-
2007
- 2007-09-20 IL IL186131A patent/IL186131A0/en unknown
- 2007-09-25 ZA ZA200708188A patent/ZA200708188B/xx unknown
-
2010
- 2010-05-05 AU AU2010201801A patent/AU2010201801A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2407529C2 (ru) | 2010-12-27 |
| NZ561950A (en) | 2010-09-30 |
| BRPI0609299A2 (pt) | 2010-03-23 |
| JP2008538751A (ja) | 2008-11-06 |
| AU2010201801A1 (en) | 2010-05-27 |
| EP1874268A1 (en) | 2008-01-09 |
| MX2007012103A (es) | 2007-11-20 |
| WO2006109183A1 (en) | 2006-10-19 |
| AU2006233345A1 (en) | 2006-10-19 |
| US20080193542A1 (en) | 2008-08-14 |
| RU2007137846A (ru) | 2009-06-20 |
| ZA200708188B (en) | 2008-10-29 |
| CN101166514A (zh) | 2008-04-23 |
| KR20070119678A (ko) | 2007-12-20 |
| CA2605153A1 (en) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200708188B (en) | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions | |
| HUS2200028I1 (hu) | Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések | |
| ZA200707440B (en) | Compositions and methods of making sustained release liquid formulations | |
| HUS1700033I1 (hu) | Illékony alkilezõszerek stabilizált készítményei és eljárások azok alkalmazására | |
| IL186469A0 (en) | Nanoparticulate and controlled release compositions comprising cyclosporine | |
| IL183843A (en) | Composition of microscopic particles and methods for synthesizing them | |
| IL190885A0 (en) | Immunogenic compositions and methods of use | |
| PT1973549T (pt) | Métodos e composições para administração de ferro | |
| ZA200807398B (en) | Compositions and methods for enhancing the antioxidant status of animals | |
| IL190239A0 (en) | Pharmaceutical gallium compositions and methods | |
| EP1968526A4 (en) | FOAMING DENTAL COMPOSITIONS AND METHODS | |
| ZA200711068B (en) | Injectable compositions and process for preparation of such compositions | |
| ZA200810162B (en) | Phenylphrine pulsed release formulations and pharmaceutical compositions | |
| GB0720887D0 (en) | Nanoparticulate and controlled release compositions comprising prostaglandin derivatives | |
| EP2046109A4 (en) | PHOTOSYNTHETIC ORGANISMS, COMPOSITIONS AND METHODS FOR GENERATING THESE ORGANISMS | |
| GB0722040D0 (en) | Sustained release methotrexate formulations and methods of use thereof | |
| GB0722530D0 (en) | Extended release compositions and methods for their manufacture 853 | |
| ZA200806601B (en) | Cryoprotective compositions and methods of using same | |
| IL192588A0 (en) | Cryoprotective compositions and methods of using same | |
| LT1973549T (lt) | Būdai ir kompozicijos, skirti geležies įvedimui | |
| IL196588A0 (en) | Photosyntheticorganisms and compositions and methods of generating same |